These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25939300)

  • 1. Lipid management in human immunodeficiency virus.
    Myerson M
    Cardiol Clin; 2015 May; 33(2):277-98. PubMed ID: 25939300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid Management in Human Immunodeficiency Virus.
    Myerson M
    Endocrinol Metab Clin North Am; 2016 Mar; 45(1):141-69. PubMed ID: 26893003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of lipid disorders in patients living with HIV.
    Myerson M; Malvestutto C; Aberg JA
    J Clin Pharmacol; 2015 Sep; 55(9):957-74. PubMed ID: 25651539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyslipidemia and lipid management in HIV-infected patients.
    Lo J
    Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):144-7. PubMed ID: 21297466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidemia in HIV patients.
    Tungsiripat M; Aberg JA
    Cleve Clin J Med; 2005 Dec; 72(12):1113-20. PubMed ID: 16392725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid metabolism in treated HIV Infection.
    Dubé MP; Cadden JJ
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of dyslipidemia in patients with human immunodeficiency virus.
    Shalit P
    Rev Cardiovasc Med; 2014; 15 Suppl 1():S38-46. PubMed ID: 24987862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.
    Liu E; Armstrong C; Spiegelman D; Chalamilla G; Njelekela M; Hawkins C; Hertzmark E; Li N; Aris E; Muhihi A; Semu H; Fawzi W
    Clin Infect Dis; 2013 Jun; 56(12):1820-8. PubMed ID: 23449270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management considerations for dyslipidemia in HIV-infected individuals.
    Kirchner JT
    Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
    Dubé MP; Sprecher D; Henry WK; Aberg JA; Torriani FJ; Hodis HN; Schouten J; Levin J; Myers G; Zackin R; Nevin T; Currier JS;
    Clin Infect Dis; 2000 Nov; 31(5):1216-24. PubMed ID: 11073755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of antiretroviral medications on fasting lipid parameters.
    Guaraldi G; Santoro A; Stentarelli C; Luzi K
    Rev Cardiovasc Med; 2014; 15 Suppl 1():S30-7. PubMed ID: 24987861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid lowering in liver and chronic kidney disease.
    Herrick C; Litvin M; Goldberg AC
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):339-52. PubMed ID: 24840263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
    Samineni D; Fichtenbaum CJ
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):995-1004. PubMed ID: 20604734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid management in patients who have HIV and are receiving HIV therapy.
    Aberg JA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):207-22. PubMed ID: 19217520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
    Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular risk and dyslipidemia management in HIV-infected patients.
    Stein JH
    Top Antivir Med; 2012; 20(4):129-33; quiz 123-4. PubMed ID: 23154252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America.
    Aberg JA; Kaplan JE; Libman H; Emmanuel P; Anderson JR; Stone VE; Oleske JM; Currier JS; Gallant JE;
    Clin Infect Dis; 2009 Sep; 49(5):651-81. PubMed ID: 19640227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
    Rokx C; Verbon A; Rijnders BJ
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.